Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Noxopharm Ltd banner

Noxopharm Ltd
ASX:NOX

Watchlist Manager
Noxopharm Ltd Logo
Noxopharm Ltd
ASX:NOX
Watchlist
Price: 0.059 AUD
Market Cap: AU$17.2m
Write Note Create Alert Ask AI

Noxopharm Ltd
Investor Relations

Noxopharm Ltd. engages in the research and development of drugs. The company is headquartered in Gordon, New South Wales. The company went IPO on 2016-08-09. The firm is focused on the treatment of cancer and cytokine release syndrome or septic shock. The firm is engaged in the drug development program, which focuses on the treatment of pancreatic cancer and glioblastoma. The firm's lead drug candidate is called Veyonda (NOX66), which is a therapy developed for chemotherapy and radiotherapy in the treatment of late-stage cancers. Its drug candidate is in Phase II clinical trials. The firm's four pillar oncology program include externally delivered radiation (DARRT) Internally delivered radiation (LuPIN), Checkpoint inhibitors (IONIC) and Chemotherapy (CEP).

Show more
Loading
NOX
S&P/ASX 300
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Gisela Mautner
CEO, Executive MD & Director
No Bio Available
Mr. Shawn Van Boheemen FCPA, J.P.
Chief Financial Officer
No Bio Available
Ms. Jeanette Bell Ph.D.
Chief Operating Officer
No Bio Available
Dr. John Wilkinson B.Sc., Ph.D.
Chief Scientific Officer of Oncology
No Bio Available
Dr. Olivier Laczka B.S., M.Sc., Ph.D.
Chief Scientific Officer of Inflammation
No Bio Available
Mr. David James Franks BEc, C.A., F Fin, J.P.
Company Secretary
No Bio Available

Contacts

Address
NEW SOUTH WALES
Gordon
Suite 3 Level 4, 828 Pacific Highway
Contacts
+61291442223.0
www.noxopharm.com
sparklesyt

See Also

Summary
NOX intrinsic value, competitors valuation, and company profile.
DCF Valuation
NOX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
NOX stock valuation using valuation multiples.
Wall Street Estimates
NOX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
NOX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 316,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.